Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.

Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.

The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors.

The company is headquartered in Doylestown, Pennsylvania.